Evidence map›Paper›PMID 32496010›Full record

ArticleESC heart failure2020

Clinical predictors of all-cause mortality in patients presenting to specialist heart failure clinic with raised NT-proBNP and no heart failure.

Pankaj Garg, Steven Wood, Andrew J Swift, Graham Fent, Nigel Lewis, Dominic Rogers, Alexander Rothman, Athanasios Charalampopoulos, Abdallah Al-Mohammad

Abstract read
In one paragraph

Article in ESC heart failure, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Pankaj GargDepartment of Infection, Immunity & Cardiovascular Disease, University of Sheffield, Sheffield, UK.ORCID 0000-0002-5483-169X
Steven WoodSheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
Andrew J SwiftDepartment of Infection, Immunity & Cardiovascular Disease, University of Sheffield, Sheffield, UK.
Graham FentSheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.ORCID 0000-0003-3343-9872
Nigel LewisSheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
Dominic RogersSheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
Alexander RothmanDepartment of Infection, Immunity & Cardiovascular Disease, University of Sheffield, Sheffield, UK.ORCID 0000-0002-7847-4500
Athanasios CharalampopoulosSheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
Abdallah Al-MohammadDepartment of Infection, Immunity & Cardiovascular Disease, University of Sheffield, Sheffield, UK.ORCID 0000-0001-6517-8692

Funding

Wellcome TrustWellcome Trust 205188/Z/16/ZWellcome Trust 206632/Z/17/Z
6 · The paper itself

Abstract

aimsClinical outcomes for patients suspected of having heart failure (HF) who do not meet the diagnostic criteria of any type of HF by echocardiography remain unknown. The aim of this study was to investigate the clinical predictors of all-cause mortality in patients with suspected HF, a raised N-terminal pro-b-type natriuretic peptide (NTproBNP) and who do not meet the diagnostic criteria of any type of HF by echocardiography. METHODS AND

resultsRelevant data were taken from the Sheffield HEArt Failure (SHEAF) registry (222349P4). The inclusion criteria were presence of symptoms raising suspicion of HF, NTproBNP > 400 pg/mL, and preserved left ventricular function. Exclusion criteria were any type of HF by echocardiography. The outcome was defined as all-cause mortality. Cox proportional-hazards regression model was used to investigate the association between the survival time of patients and clinical variables; 1031 patients were identified with NTproBNP > 400 pg/mL but who did not have echocardiographic evidence of HF. All-cause mortality was 21.5% (222 deaths) over the mean follow-up (FU) period of 6 ± 2 years. NTproBNP was similar in patients who were alive or dead (P = 0.96). However, age (HR 1, P < 0.01), chronic kidney disease (CKD, HR 1.2, P < 0.01), chronic pulmonary obstructive disease (COPD, HR 1.6, P < 0.01), dementia (HR 5.9, P < 0.01), male gender (HR 1.4, P < 0.01), first-degree atrioventricular block (HR 2.1, P < 0.01), left axis deviation (HR 1.6, P = 0.04), and diabetes (HR 1.4, P = 0.03) were associated with all-cause mortality. In multivariate regression, age, gender, CKD stage, COPD, and dementia were independently associated with mortality. In patients with NTproBNP > 627 pg/mL, NYHA class predicted death (II, 19.6%; III, 27.4%; IV, 66.7%; P < 0.01).

conclusionsPatients with no HF on echocardiography but raised NTproBNP suffer excess mortality particularly in the presence of certain clinical variables. Age, male gender, worsening CKD stage, presence of COPD, and dementia are independently associated with all-cause mortality in these patients. An NTproBNP > 627 pg/mL coupled with NYHA class could identify patients at greatest risk of death.

Indexed as

Heart FailureNatriuretic Peptide, BrainHumansMalePeptide FragmentsPrognosisNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)EchocardiographyElectrocardiographyHeart failureLeft ventricular functionNatriuretic peptidesObservational study

Identifiers

PMID32496010
PMCPMC7373941

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.